ReviewWorld journal of gastrointestinal pharmacology and therapeutics2017
Phage therapy: An alternative to antibiotics in the age of multi-drug resistance.
Review in World journal of gastrointestinal pharmacology and therapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 594 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
594 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- From genomic signals to prediction tools: a critical feature analysis and rigorous benchmark for phage-host prediction.Briefings in bioinformatics · 2025Pooled it
- A systematic review of preclinical studies on therapeutic potential of mesenchymal stem/stromal cells and their secretome in bacterial infections.Stem cell research & therapy · 2025Pooled it
- Bacteriophage vB_SalS_KY05 controlsThe veterinary quarterly · 2026Article
- Phage vB_KpnM_NB cocktail synergizing with amikacin in inhibiting persister cells ofApplied and environmental microbiology · 2026Article
- Phage Genomics and Bioinformatics in Therapeutic Development: Evidence Limits, Validation Gates, and Translational Decision-Making.Pharmaceuticals (Basel, Switzerland) · 2026Review
- Systems engineering of engineered live biotherapeutics: A discovery-to-translation framework for streamlining microbiome therapeutic development.Journal of controlled release : official journal of the Controlled Release Society · 2026Review
- Rational Design of a Phage Cocktail for Effective Control of Multidrug-Resistant UropathogenicAntibiotics (Basel, Switzerland) · 2026Article
- Eradication of catheter-associated MDR Acinetobacter baumannii biofilms mediated by novel phage encoded depolymerase activity.NPJ biofilms and microbiomes · 2026Article
- Bacteriophage therapy and antimicrobial resistance: a scoping review using the "One Health" framework.Infection · 2026Review
- Gut microbiota in poultry: Roles in nutrition, metabolism and production performance.Poultry science · 2026Review
- Prevalence and Antimicrobial Resistance ofInfectious disease reports · 2026Article
- Phage as a prospective arsenal against superbugs.Molecular biology reports · 2026Review
- Characterization ofMicrobiology spectrum · 2026Article
- Bacteriophage cocktails and bacterial coevolution: a systematic review of resistance prevention strategies against multidrug-resistant pathogens in sewage water.Iranian journal of microbiology · 2026Article
- Isolation and characterization of bacteriophages against antibiotic-resistanceIranian journal of microbiology · 2026Article
- Large-Scale Structural Dynamics in the Tail Fiber Modulate the Infective Transition of the T7 Bacteriophage.Small (Weinheim an der Bergstrasse, Germany) · 2026Article
- Synergistic potential of probiotics and bacteriophages in combating multidrug-resistant microbial infections: A novel therapeutic strategy for the post-antibiotic era.New microbes and new infections · 2026Review
- Impact of Lysine-Mediated C-Terminal Dimerization of Anoplin on Killing Kinetics and Antibiotic Interaction Profiles.Microorganisms · 2026Article
- Human Infections Caused by Flavobacteriales: Clinical Characteristics and Antimicrobial Susceptibility Patterns.Infectious disease reports · 2026Review
- Bacterial immune systems.Antonie van Leeuwenhoek · 2026Review
534 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The practice of phage therapy, which uses bacterial viruses (phages) to treat bacterial infections, has been around for almost a century. The universal decline in the effectiveness of antibiotics has generated renewed interest in revisiting this practice. Conventionally, phage therapy relies on the use of naturally-occurring phages to infect and lyse bacteria at the site of infection. Biotechnological advances have further expanded the repertoire of potential phage therapeutics to include novel strategies using bioengineered phages and purified phage lytic proteins. Current research on the use of phages and their lytic proteins, specifically against multidrug-resistant bacterial infections, suggests phage therapy has the potential to be used as either an alternative or a supplement to antibiotic treatments. Antibacterial therapies, whether phage- or antibiotic-based, each have relative advantages and disadvantages; accordingly, many considerations must be taken into account when designing novel therapeutic approaches for preventing and treating bacterial infections. Although much is still unknown about the interactions between phage, bacteria, and human host, the time to take phage therapy seriously seems to be rapidly approaching.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.